Home
About
Overview
Sharing Data
ORCID
Help
History (15)
End-of-life practices: An ethical framework for clinicians.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Principled decisions and virtuous care: an ethical assessment of the SIAARTI Guidelines for allocating intensive care resources.
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. Leuk Lymphoma. 2001 Jul; 42(3):417-27.
View in:
PubMed
subject areas
Antibiotics, Antineoplastic
Biological Transport
Cell Division
Cell Survival
DNA Primers
Drug Synergism
Gene Expression Regulation, Neoplastic
Genes, p53
Hematopoietic Stem Cells
Humans
Idarubicin
Kinetics
Lymphoma
Oligodeoxyribonucleotides
Polymerase Chain Reaction
Time Factors
Tumor Cells, Cultured
Tumor Suppressor Protein p53
authors with profiles
Michael Bishop